ClinicalTrials.gov
public full text
Public Domain
Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab to induce clinical and serological remission in patients with relapsing PR3-ANCA granulomatosis with polyangiitis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study#981101
- Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis#1058980
- Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study#884991
- Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma#910497
- Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma#807307
Record · ID 890907
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive